We are developing an extensive pipeline of bi-functional anti-cancer therapeutics. 
These engineered cytokines/cytokine receptors exhibit new pharmacological properties including:

  • Robust immune cell activation contemporaneously with the blockage of immune-suppressive factors.

  • Long-lasting half-life, which reduces the number of dose per patient.

  • Enhanced tumor infiltration by cytotoxic immune cells.

  • Limited toxicity.

Our pipeline targets a broad range of solid and hematological malignancies.
The designed cytokines can be used as stand-alone therapies or in combination with others strategies such as
immune-checkpoint blockers or cell-based therapeutics (CAR T cells and dendritic cell-based vaccines).